Drugs / ACIT-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03096093 | Apr 2017 → Dec 2026 expected | cancer | Cancer Vaccines Limited | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACIT-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03096093 ↗ |
| Action | Activate | “ACIT-1 is designed to stimulate tumour antigen-specific T cells to respond and kill cancer cells.” NCT03096093 ↗ |
| Modality | Cell therapy | “allogeneic cell immunotherapy” NCT03096093 ↗ |
| Route | Other | “Intradermal injection of ACIT-1 cellular immunotherapy” NCT03096093 ↗ |